TY - JOUR
T1 - Diffusion-weighted magnetic resonance imaging as an early prognostic marker of chemoradiotherapy response in squamous cell carcinoma of the anus
T2 - An individual patient data meta-analysis
AU - Hanekamp, Bettina A
AU - Virdee, Pradeep S
AU - Goh, Vicky
AU - Jones, Michael
AU - Hvass Hansen, Rasmus
AU - Hjorth Johannesen, Helle
AU - Schulz, Anselm
AU - Serup-Hansen, Eva
AU - Guren, Marianne G
AU - Muirhead, Rebecca
N1 - © 2024 The Authors. Published by Elsevier B.V. on behalf of European Society of Radiotherapy & Oncology.
PY - 2024/7
Y1 - 2024/7
N2 - BACKGROUND AND PURPOSE: Squamous cell carcinoma of the anus (SCCA) can recur after chemoradiotherapy (CRT). Early prediction of treatment response is crucial for individualising treatment. Existing data on radiological biomarkers is limited and contradictory. We performed an individual patient data meta-analysis (IPM) of four prospective trials investigating whether diffusion-weighted (DW) magnetic resonance imaging (MRI) in weeks two to three of CRT predicts treatment failure in SCCA.MATERIAL AND METHODS: Individual patient data from four trials, including paired DW-MRI at baseline and during CRT, were combined into one dataset. The association between ADC volume histogram parameters and treatment failure (locoregional and any failure) was assessed using logistic regression. Pre-defined analysis included categorising patients into a change in the mean ADC of the delineated tumour volume above and below 20%.RESULTS: The study found that among all included 142 patients, 11.3 % (n = 16) had a locoregional treatment failure. An ADC mean change of <20 % and >20 % resulted in a locoregional failure rate of 16.7 % and 8.0 %, respectively. However, no other ADC-based histogram parameter was associated with locoregional or any treatment failure.CONCLUSIONS: DW-MRI standard parameters, as an isolated biomarker, were not found to be associated with increased odds of treatment failure in SCCA in this IPM. Radiological biomarker investigations involve multiple steps and can result in heterogeneous data. In future, it is crucial to include radiological biomarkers in large prospective trials to minimize heterogeneity and maximize learning.
AB - BACKGROUND AND PURPOSE: Squamous cell carcinoma of the anus (SCCA) can recur after chemoradiotherapy (CRT). Early prediction of treatment response is crucial for individualising treatment. Existing data on radiological biomarkers is limited and contradictory. We performed an individual patient data meta-analysis (IPM) of four prospective trials investigating whether diffusion-weighted (DW) magnetic resonance imaging (MRI) in weeks two to three of CRT predicts treatment failure in SCCA.MATERIAL AND METHODS: Individual patient data from four trials, including paired DW-MRI at baseline and during CRT, were combined into one dataset. The association between ADC volume histogram parameters and treatment failure (locoregional and any failure) was assessed using logistic regression. Pre-defined analysis included categorising patients into a change in the mean ADC of the delineated tumour volume above and below 20%.RESULTS: The study found that among all included 142 patients, 11.3 % (n = 16) had a locoregional treatment failure. An ADC mean change of <20 % and >20 % resulted in a locoregional failure rate of 16.7 % and 8.0 %, respectively. However, no other ADC-based histogram parameter was associated with locoregional or any treatment failure.CONCLUSIONS: DW-MRI standard parameters, as an isolated biomarker, were not found to be associated with increased odds of treatment failure in SCCA in this IPM. Radiological biomarker investigations involve multiple steps and can result in heterogeneous data. In future, it is crucial to include radiological biomarkers in large prospective trials to minimize heterogeneity and maximize learning.
UR - http://www.scopus.com/inward/record.url?scp=85200255492&partnerID=8YFLogxK
U2 - 10.1016/j.phro.2024.100618
DO - 10.1016/j.phro.2024.100618
M3 - Journal article
C2 - 39188809
SN - 2405-6316
VL - 31
JO - Physics and imaging in radiation oncology
JF - Physics and imaging in radiation oncology
M1 - 100618
ER -